ADC

198개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved198 programs
ADCCurated CoreFDAGileadSN-38 (topoisomerase I inhi…Approved

sacituzumab govitecan (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy)

Metastatic triple-negative breast cancer, pretreated HR+/HER2− breast cancer · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 242Status Approved
ADCCurated CoreFDADaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 240Status Approved
ADCCurated CoreFDAAstellasMMAE (monomethyl auristatin…Approved

enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv)

Locally advanced or metastatic urothelial carcinoma · Nectin-4

#Nectin-4#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 201Status Approved
ADCCurated CoreFDAstaleSeagenvedotin and the anti-HER2 t…Approved

brentuximab vedotin (Adcetris)

Hodgkin's Disease · Hodgkin Disease

#HodgkinDisease#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 180Status Approved
ADCCurated CoreFDARocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 178Status Approved
ADCCurated CoreFDARemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 159Status Active
ADCCurated CoreFDAstaleRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA-approved#BioJungboMoa-pick+5
Trials 91Status Recruiting
ADCCurated CoreFDAGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 78Status Discontinued
ADCCurated CoreFDADaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk)

HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
ADCCurated CoreFDAAbbVieDM4 (maytansinoid, tubulin …Approved

mirvetuximab soravtansine (Elahere, IMGN853, mirvetuximab-soravtansine-gynx)

FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer · FRα (folate receptor alpha)

#FRfolatereceptoralpha#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 32Status Approved
ADCStandard DatabaseFDAstaleDaiichi SankyoApproved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Approved#FDA-approved#antibody-drug-conjugate+3
Trials 24Status Approved
ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
ADCCurated CoreFDAAbbVieMMAE (microtubule inhibitor)Approved

telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv)

Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression · c-Met

#c-Met#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 12Status Approved
ADCLimited DataFDAstaleRochePreclinical

Polatuzumab Vedotin-Piiq (Polatuzumab Vedotin-Piiq)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Preclinical#FDA-approved#antibody-drug-conjugate+1
Trials 1Status Active
ADCLimited DataFDAGenmabApproved

TISOTUMAB VEDOTIN-TFTV (TISOTUMAB VEDOTIN-TFTV)

FDA-approved indication · See label

#Seelabel#ADC#Approved#FDA-approved#antibody-drug-conjugate+2
Trials 0Status Approved
ADCStandard DatabasestaleAdcendo ApSPhase 2

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma · Metastatic Soft Tissue Sarcoma

#MetastaticSoftTissueSarcoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 226Status Recruiting
ADCLimited DatastaleSeagenvedotin combined with the i…Preclinical

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma · CD30

#CD30#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 219Status Active
ADCStandard DatabasestaleSeagenVedotin: A Retrospective Co…Approved

Bv (Brentuximab Vedotin, Brentuximab Vedotin (Bv))

Hodgkin Lymphoma (Category) · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Approved#Popular#antibody-drug-conjugate+4
Trials 195Status Active
ADCLimited DatastaleRochevedotin plus rituximab, cyc…Phase 2

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 183Status Active
ADCStandard DatabasestaleRochevedotin plus rituximab, cyc…Phase 2

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 177Status Discontinued

1 / 10 pages

← PreviousNext →